US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

CNS/Neurology Market Research Reports & Industry Analysis

RSS Feeds

CNS/Neurology Industry Research & Market Reports

1  2    4    6  7  8  9  10  
Attention Deficit Hyperactivity Disorder Partnering 2009-2014
4/1/2014 | published by: Current Partnering
... report provides an analysis of attention deficit disorder partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors attention deficit ...  |  read more...
USD 695
Bipolar Disorder Partnering 2009-2014
4/1/2014 | published by: Current Partnering
... of bipolar disorder partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bipolar disorder technology. These deals tend to ...  |  read more...
USD 695
Anxiety Partnering 2009-2014
4/1/2014 | published by: Current Partnering
... deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors anxiety technology. These deals tend to be multicomponent, starting with collaborative ...  |  read more...
USD 695
Market Highlights: US Schizophrenia – 2014
5/1/2014 | published by: Fore Pharma
... the US schizophrenia market size estimates for 2013, market share forecast for six years to 2019, schizophrenia drugs market share, schizophrenia drugs sales estimates, schizophrenia drugs sales forecast, and schizophrenia late stage pipeline products.This research ...  |  read more...
USD 990
High-Grade Glioma - Pipeline Review, H1 2014
6/15/2014 | published by: Global Markets Direct
... therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Global Anti-Migraine Drugs Market: Trends and Opportunities (2014-19)
6/1/2014 | published by: Daedal Research
... World’s Top 20 disabling medical illnesses. It is anticipated that launches of many generic migraine drugs over the next several years will steadily increase diagnosis and drug-treatment rates, leading to sustained annual global growth of ...  |  read more...
USD 700
Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Tinnitus - Pipeline Review, H1 2014
6/15/2014 | published by: Global Markets Direct
... Tinnitus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It ...  |  read more...
USD 2,000
Savella (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Market Highlights: Spain Attention Deficit Hyperactivity Disorder – 2014
5/1/2014 | published by: Fore Pharma
... hyperactivity disorder drug sales forecast in Spain. The research includes Spain attention deficit hyperactivity disorder market size estimates for 2013, market share forecast for six years to 2019, attention deficit hyperactivity disorder drugs market share, ...  |  read more...
USD 990
Market Highlights: Germany Attention Deficit Hyperactivity Disorder – 2014
5/1/2014 | published by: Fore Pharma
... hyperactivity disorder drug sales forecast in Germany. The research includes Germany attention deficit hyperactivity disorder market size estimates for 2013, market share forecast for six years to 2019, attention deficit hyperactivity disorder drugs market share, ...  |  read more...
USD 990
Market Highlights: France Attention Deficit Hyperactivity Disorder – 2014
5/1/2014 | published by: Fore Pharma
... hyperactivity disorder drug sales forecast in France. The research includes France attention deficit hyperactivity disorder market size estimates for 2013, market share forecast for six years to 2019, attention deficit hyperactivity disorder drugs market share, ...  |  read more...
USD 990
Market Highlights: Japan Attention Deficit Hyperactivity Disorder – 2014
5/1/2014 | published by: Fore Pharma
... hyperactivity disorder drug sales forecast in Japan. The research includes Japan attention deficit hyperactivity disorder market size estimates for 2013, market share forecast for six years to 2019, attention deficit hyperactivity disorder drugs market share, ...  |  read more...
USD 990
Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
... trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Glioblastoma Multiforme (GBM). It includes an overview of the trial numbers and their recruitment status as per the site ...  |  read more...
USD 2,500
Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
... report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across ...  |  read more...
USD 2,500
Recurrent Medulloblastoma Global Clinical Trials Review, H1, 2014
3/31/2014 | published by: GlobalData
... information and data relating to the clinical trials on Recurrent Medulloblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ...  |  read more...
USD 2,500
PharmaPoint: Migraine - Current and Future Players
3/31/2014 | published by: GlobalData
... the companies in the rapidly growing Migraine Market. The report identifies and analyses the key companies shaping and driving the global Migraine market. The report provides insight into the competitive Migraine landscape, including new companies ...  |  read more...
USD 2,995
Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2014
3/31/2014 | published by: Global Markets Direct
... report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ...  |  read more...
USD 2,000
1  2    4    6  7  8  9  10